Alpha 2.0
Login Register
» Authors » J Codony-Servat

J Codony-Servat

Explore the profile of J Codony-Servat including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 494
Followers 0
Related Specialties
Oncology
Biochemistry
Pharmacology
Top 10 Co-Authors
J Albanell
J Baselga
S Sauleda
C Juarez
J Arribas
J L Rodriguez-Sanchez
F Rojo
R Gimeno
R I Nicholson
J Domingo-Domenech
Published In
Cancer Res
J Immunol
Br J Cancer
Biochem Pharmacol
Lung Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC
Rodriguez-Abreu D, Cobo M, Garcia-Roman S, Viteri-Ramirez S, Jordana-Ariza N, Garcia-Pelaez B, et al.
Lung Cancer . 2021 Dec; 164:8-13. PMID: 34971901
Introduction: Combination of anti-EGFR monoclonal antibodies or immune checkpoint inhibitors with TKIs has shown minimal benefit in EGFR mutant (EGFR-mut) NSCLC patients. Consequently, new combination approaches are needed. Patients And...
2.
Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse
Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S, et al.
Br J Cancer . 2005 Nov; 93(11):1285-94. PMID: 16278667
Nuclear factor (NF)-kappaB/p65 regulates the transcription of a wide variety of genes involved in cell survival, invasion and metastasis. We characterised by immunohistochemistry the expression of NF-kappaB/p65 protein in six...
3.
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments
Albanell J, Codony-Servat J, Rojo F, Del Campo J, Sauleda S, Anido J, et al.
Cancer Res . 2001 Aug; 61(17):6500-10. PMID: 11522647
The expression of the activated mitogen-activated kinases/extracellular signal-regulated kinases (ERKs) ERK1 and ERK2 was characterized in 101 humanhead and neck squamous carcinoma specimens. Activated ERK1/2were detected at different levels in...
4.
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells
Molina M, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J
Cancer Res . 2001 Jun; 61(12):4744-9. PMID: 11406546
HER2 is a ligand-less tyrosine kinase receptor of the ErbB family that is frequently overexpressed in breast cancer. It undergoes proteolytic cleavage that results in the release of the extracellular...
5.
Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells
Codony-Servat J, Albanell J, Lopez-Talavera J, Arribas J, Baselga J
Cancer Res . 1999 Mar; 59(6):1196-201. PMID: 10096547
HER2/neu, a Mr 185,000 tyrosine kinase receptor that is overexpressed in breast cancer, undergoes proteolytic cleavage of its extracellular domain (ECD). In contrast with other membrane-bound proteins, including growth factor...
6.
The two isoforms of the 90-kDalton nucleolus organizer region autoantigen (upstream binding factor) bind with different avidity to DNA modified by the antitumor drug cisplatin
Codony-Servat J, Gimeno R, Gelpi C, Rodriguez-Sanchez J, Juarez C
Biochem Pharmacol . 1996 May; 51(9):1131-6. PMID: 8645334
It has been previously described that some proteins containing HMG boxes are able to bind more strongly to DNA modified with cis-diamminedichloroplatinum (II) (cisplatin) than to unmodified DNA. In the...
7.
Stat1 implication in the immune response to superantigens in vivo
Gimeno R, Codony-Servat J, Plana M, Rodriguez-Sanchez J, Juarez C
J Immunol . 1996 Feb; 156(4):1378-86. PMID: 8568237
We analyzed the activation and changes in the protein level of STAT1 as a consequence of in vivo treatment with superantigens. Ninety minutes after i.p. injection of the staphylococcal enterotoxin...